Nothing Special   »   [go: up one dir, main page]

BRPI0507492A - formulações de microemulsão compreendendo antagonistas de substáncia p - Google Patents

formulações de microemulsão compreendendo antagonistas de substáncia p

Info

Publication number
BRPI0507492A
BRPI0507492A BRPI0507492-4A BRPI0507492A BRPI0507492A BR PI0507492 A BRPI0507492 A BR PI0507492A BR PI0507492 A BRPI0507492 A BR PI0507492A BR PI0507492 A BRPI0507492 A BR PI0507492A
Authority
BR
Brazil
Prior art keywords
substance
microemulsion formulations
substance antagonists
antagonists
arylcarbonylamino
Prior art date
Application number
BRPI0507492-4A
Other languages
English (en)
Inventor
Barbara Lueckel
Waltraud Bueb
Isabel Ottinger
Thomas Reinhart
Angelika Ries
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0507492A publication Critical patent/BRPI0507492A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FORMULAçõES DE MICROEMULSãO COMPREENDENDO ANTAGONISTAS DE SUBSTáNCIA P.A presente invenção refere-se a composições farmacêuticas dispersáveis em que o agente ativo é um antagonista de substância P, em particular uma amida de ácido 5-aril-4(R)-arilcarbonilamino-pent-2-enoico, que é útil para o tratamento e prevenção de síndrome respiratória incluindo asma e doença pulmonar obstrutiva crõnica, distúrbios de intestino incluindo síndrome do intestino irritável, incontinência urinária e tosse.
BRPI0507492-4A 2004-02-06 2005-02-04 formulações de microemulsão compreendendo antagonistas de substáncia p BRPI0507492A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402679.5A GB0402679D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2005/001166 WO2005074891A1 (en) 2004-02-06 2005-02-04 Microemulsion formulations comprising particular substance p antagonists

Publications (1)

Publication Number Publication Date
BRPI0507492A true BRPI0507492A (pt) 2007-07-17

Family

ID=31985813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507492-4A BRPI0507492A (pt) 2004-02-06 2005-02-04 formulações de microemulsão compreendendo antagonistas de substáncia p

Country Status (15)

Country Link
US (1) US20080254113A1 (pt)
EP (1) EP1715848B1 (pt)
JP (1) JP2007520521A (pt)
CN (1) CN1929817B (pt)
AT (1) ATE475409T1 (pt)
AU (1) AU2005210134B2 (pt)
BR (1) BRPI0507492A (pt)
CA (1) CA2553658A1 (pt)
DE (1) DE602005022558D1 (pt)
ES (1) ES2349647T3 (pt)
GB (1) GB0402679D0 (pt)
PL (1) PL1715848T3 (pt)
PT (1) PT1715848E (pt)
RU (1) RU2397759C2 (pt)
WO (1) WO2005074891A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
RU2481822C1 (ru) * 2012-02-21 2013-05-20 Автономная некоммерческая организация "Институт медико-биологических исследований и технологий" (АНО "ИМБИИТ") Микроэмульсионные композиции для создания трансдермальных и трансмукозальных форм фармацевтических средств и косметических препаратов и способ их получения
CN104968330A (zh) * 2013-01-14 2015-10-07 因佛斯特医疗有限公司 用于治疗剧痛的组合物及方法
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
EP0999838B1 (en) * 1997-07-29 2002-04-03 PHARMACIA & UPJOHN COMPANY Self-emulsifying formulation for lipophilic compounds
DK1107744T3 (da) * 1998-08-25 2003-07-28 Wolfgang Mueller Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs

Also Published As

Publication number Publication date
EP1715848A1 (en) 2006-11-02
GB0402679D0 (en) 2004-03-10
PL1715848T3 (pl) 2011-01-31
ATE475409T1 (de) 2010-08-15
CA2553658A1 (en) 2005-08-18
DE602005022558D1 (de) 2010-09-09
EP1715848B1 (en) 2010-07-28
US20080254113A1 (en) 2008-10-16
CN1929817A (zh) 2007-03-14
AU2005210134A1 (en) 2005-08-18
WO2005074891A1 (en) 2005-08-18
RU2006131788A (ru) 2008-03-20
RU2397759C2 (ru) 2010-08-27
JP2007520521A (ja) 2007-07-26
PT1715848E (pt) 2010-10-21
ES2349647T3 (es) 2011-01-07
AU2005210134B2 (en) 2008-05-22
CN1929817B (zh) 2012-04-25

Similar Documents

Publication Publication Date Title
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
TR201820559T4 (tr) Azelastin içeren kompozisyonlar ve bunların kullanım metotları.
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
MXPA02011311A (es) Composicion novedosa.
HUP0401614A2 (hu) PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20063810L (no) Hydroisoindolintakykininreseptorantagonister
HRP20140707T1 (hr) KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA
CY1112968T1 (el) Συνδυασμος αντιχολινεργικων και αναστολεων της φωσφοδιεστερασης τυπου 4 για τη θεραπεια αναπνευστικων νοσων
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
WO2007002457A3 (en) Hydroisoindoline tachykinin receptor antagonists
EP1773374A4 (en) AGAINST FGF2 AS AN ACTIVE AGENT FOR THE TREATMENT AND PREVENTION OF ASTHMA AND CHRONIC OBSTRUCTIVE LUNG DISEASE
BRPI0507492A (pt) formulações de microemulsão compreendendo antagonistas de substáncia p
EA200601880A1 (ru) Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
WO2005011608A3 (en) PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR
WO2007081897A3 (en) Fused triazole tachykinin receptor antagonists
EP2315589A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.